Transient increase in skeletal-related events after discontinuation of high-dose denosumab in cancer patients
SREs increased significantly 6-15 months after high-dose denosumab discontinuation. Elevated ALP was associated with post-discontinuation SREs. These findings emphasize that discontinuation contributes to SRE risk, possibly via rebound bone resorption, and underscore the importance of continuation of therapy whenever possible.
Authors
- Nobuhiko Yokoyama (ORCID: https://orcid.org/0000-0002-3013-3205)
- Eriko Tokunaga (ORCID: https://orcid.org/0000-0002-1640-5315)
- Taito Esaki
- Takahito Negishi (ORCID: https://orcid.org/0000-0002-6645-8829)
- Masafumi Yamaguchi (ORCID: https://orcid.org/0000-0002-0369-324X)
- Nokitaka Setsu (ORCID: https://orcid.org/0000-0003-0042-3321)
Institutions
- National Hospital Organization Kyushu Cancer Center (JP)
Publication Details
- Journal
- Journal of bone oncology
- Published
- 2025-10-11
- DOI
- https://doi.org/10.1016/j.jbo.2025.100717
- Citations
- 1
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.05